New breathing treatment for babies with bronchiolitis never tested
NCT ID NCT01229384
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This trial aimed to compare standard nebulized breathing treatments with a positive pressure device in infants aged 2-24 months with moderate to severe bronchiolitis. The goal was to see if the pressurized method reduced hospital admissions. However, the study was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- albuterol and racemic epinephrine delivered via positive pressure nebulization device
- What this could lead to
- If it worked, this could show a better way to deliver breathing treatments to infants with bronchiolitis, potentially reducing hospital stays.
- What could go wrong
- The study was withdrawn before any patients were enrolled, so no results exist. The approach is still experimental and unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple decision tool cut time on breathing support for sick infants?
- Could a lower oxygen threshold get kids home sooner?
- Laughing gas may soothe painful tube insertion in toddlers
- Which flow rate helps babies breathe better? new study tests two options
- AI stethoscope aims to cut unnecessary antibiotics in kids with cough
- Ultrasound vs x-ray: a new way to spot lung issues in sick babies?